Otsuka & Lundbeck v. Apotex: Aripiprazole Patents Dismissed Without Prejudice
Otsuka Pharmaceutical and H. Lundbeck brought a six-patent infringement action against Apotex in Delaware over long-acting injectable aripiprazole formulations (300 mg/vial and 400 mg/vial). After 593 days, the parties stipulated to dismissal without prejudice, with each side bearing its own costs and fees.
Six-Patent Aripiprazole Dispute Ends Without Merits Ruling in Delaware
On 30 August 2024, Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck AS filed an infringement action in the District of Delaware (Case No. 1:24-cv-01004) against Apotex, Inc., Aposherm Delaware Holdings Corporation, Apotex Corp., and Apotex Pharmachem, Inc. The complaint asserted six US patents — US11400087B2, US10525057B2, US10980803B2, US11154553B1, US11344547B2, and US11648347B2 — covering aripiprazole long-acting injectable formulations in 300 mg/vial and 400 mg/vial strengths.
The recorded basis of termination is dismissal without prejudice. The docket order states that the parties stipulated and agreed to dismiss all claims and counterclaims, with each party to bear its own costs and attorneys' fees. The court specifically retained jurisdiction over the parties for the purpose of adjudicating any issues arising from the settlement of this action.
The case closed on 15 April 2026, approximately 593 days after filing, without any merits ruling on infringement or validity. Because the dismissal is without prejudice, the plaintiffs retain the right to refile claims on the asserted patents. The specific terms of any underlying settlement arrangement are not disclosed in the available record.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 593 days
593 days from filing to dismissal in the District of Delaware
US11400087B2 — Aripiprazole long-acting injectable formulations
Any pharmaceutical company filing or maintaining an ANDA for aripiprazole long-acting injectable products in 300 mg/vial or 400 mg/vial dosage forms should treat this six-patent portfolio as a live enforcement risk. The without-prejudice dismissal means no claim has been adjudicated invalid or not infringed — the entire portfolio is available for future assertion against new or ongoing ANDA filers.
Official order — verbatim text
The stipulated dismissal order records that all claims and counterclaims are dismissed without prejudice, with parties bearing their own costs, and that the court retains jurisdiction to adjudicate issues arising from the settlement. No infringement finding, no validity ruling, and no damages determination were entered. The without-prejudice posture leaves each plaintiff's patent rights intact and each defendant's ANDA exposure unresolved on the merits.
Dismissed without prejudice: what the stipulated dismissal means for both parties
What dismissal without prejudice means in ANDA patent litigation
A dismissal without prejudice ends the current action but does not extinguish the underlying claims. The plaintiffs retain the right to refile infringement actions on the same six patents. The court also retained jurisdiction to adjudicate issues arising from the settlement, suggesting ongoing obligations between the parties, though the specific terms are not disclosed in the available record.
Claims may be refiledOtsuka and Lundbeck preserve enforcement rights across all six patents
Because the dismissal is without prejudice, Otsuka and Lundbeck's six aripiprazole injectable patents remain enforceable and no adverse merits finding was entered. The patent holders are not precluded from asserting the same patents against Apotex or other generic challengers in future proceedings. The retained court jurisdiction clause may also provide a mechanism to enforce any underlying arrangement.
No adverse merits findingApotex avoids a merits ruling but faces potential future exposure
The Apotex group entities secured a resolution without any finding of infringement or validity being entered against them. Each party bearing its own costs suggests neither side conceded a clearly dominant litigation position. However, a dismissal without prejudice means Apotex's exposure on the six asserted patents is not permanently resolved — the patents remain live and enforceable against future ANDA activity.
No infringement findingAripiprazole injectable IP remains contested — generic market entry uncertain
Six patents protecting aripiprazole 300 mg/vial and 400 mg/vial long-acting injectables remain in force and unlitigated on the merits. Other generic applicants in this space should treat these patents as active litigation risks. The retained-jurisdiction clause and the without-prejudice posture together suggest the commercial position between these specific parties may remain subject to ongoing terms not visible in the public record.
Active IP risk for genericsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Otsuka Pharmaceutical Co., Ltd. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | H. Lundbeck, AS | Individual | Search in Eureka ↗ |
| Defendant | Apotex, Inc. | Company | /Search in Eureka ↗ |
| Co-Defendant | Aposherm Delaware Holdings Corporation | Company | Search in Eureka ↗ |
| Co-Defendant | Apotex Corp. | Company | Search in Eureka ↗ |
| Co-Defendant | Apotex Pharmachem, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | A. Sasha Hoyt | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Erin M. Sommers | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | James B. Monroe | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Jeanette M. Roorda | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | John G. Day | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Laura E. Brashear | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Melanie Magdun | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Balick | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Ashby & Geddes PC | Law Firm | Representing Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | Dylan G. Sacenti | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | Greg L. Goldblatt | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | Joseph T. Jaros | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | Megan C. Haney | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | Sarah ML Wilkening | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | William A. Rakoczy | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Apotex, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the aripiprazole long-acting injectable space
Forward-looking patent and R&D intelligence derived from Otsuka and Lundbeck's six-patent aripiprazole LAI portfolio and the broader injectable antipsychotic landscape.
Otsuka's aripiprazole LAI filing activity signals layered exclusivity strategy
The six patents asserted span application numbers from US14/034727 to US17/459221, indicating a multi-generational filing programme. Monitoring Otsuka and Lundbeck's continuation and divisional activity in this family can reveal where additional formulation or method claims are being pursued — intelligence critical for generic developers planning ANDA timelines.
Continuation watchFiling trends in LAI antipsychotic formulations are accelerating
Long-acting injectable antipsychotics are a growing area of pharmaceutical patent activity, with formulation, dosing regimen, and particle size claims all being actively pursued by multiple originator firms. Understanding the density of granted and pending claims in the aripiprazole LAI space helps R&D teams identify which formulation parameters remain available for differentiated generic or 505(b)(2) development.
LAI formulation trendsApotex's patent filing activity in injectable generics reveals R&D priorities
Apotex's decision to litigate this case to a without-prejudice dismissal rather than press for invalidity findings suggests a calculated assessment of the patent portfolio's strength. Reviewing Apotex's own patent filings in sterile injectable formulation technology can signal where the company is building proprietary positions to support future generic or branded pipeline entries.
Apotex injectable IPAdjacent delivery formats may offer design-around pathways for LAI developers
The asserted patents focus on specific aripiprazole vial formulations and dosing methods. White space may exist in alternative particle engineering approaches, novel excipient combinations, or extended-dosing regimen claims not captured by the current portfolio. R&D teams can use patent landscaping to identify claim gaps before committing to formulation development programmes.
Design-around white spaceSimilar aripiprazole and LAI pharmaceutical patent cases in Delaware
Browse comparable ANDA patent infringement cases involving long-acting injectable antipsychotics litigated in the District of Delaware, including multi-patent pharmaceutical portfolio disputes.
What this case signals for the aripiprazole injectable IP landscape
Six formulation patents survive uncontested on the merits — generic market entry for long-acting aripiprazole injectables remains structurally constrained.
Without-prejudice dismissal keeps all six patents fully armed for future enforcement
No invalidity or non-infringement finding was entered. Otsuka and Lundbeck retain the ability to assert US11400087B2, US10525057B2, US10980803B2, US11154553B1, US11344547B2, and US11648347B2 against Apotex or any other generic entrant — making FTO analysis against this portfolio essential for any ANDA filer in the aripiprazole injectable space.
Retained court jurisdiction signals more than a clean walk-away
The stipulation explicitly preserves the Delaware court's jurisdiction to resolve issues arising from the settlement. This is consistent with parties having structured ongoing commercial or licensing terms. R&D and business development teams monitoring this space should note that the competitive dynamics between these specific parties may not be fully resolved despite the docket closure.
Otsuka v Apotex — key questions answered
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck AS asserted six US patents: US11400087B2, US10525057B2, US10980803B2, US11154553B1, US11344547B2, and US11648347B2. All six patents cover aripiprazole long-acting injectable formulations in 300 mg/vial and 400 mg/vial strengths.
The case was dismissed without prejudice by stipulation of all parties on 15 April 2026, with each party bearing its own costs and attorneys' fees. Dismissal without prejudice means no merits ruling was entered and the plaintiffs retain the right to refile infringement claims on the same six patents in future proceedings.
No adverse merits ruling was entered, meaning none of the six patents were found invalid or not infringed by the court. All six patents remain enforceable. The without-prejudice nature of the dismissal confirms that the patent holders can assert these patents again — against Apotex or any other generic entrant — in future litigation.
The stipulated dismissal order states that the court specifically retains jurisdiction over the parties for the purpose of adjudicating any issues arising from the settlement of this action. This language is consistent with parties having reached an underlying arrangement with ongoing obligations. The specific terms of any such arrangement are not disclosed in the available public record.
Generic developers targeting aripiprazole 300 mg/vial or 400 mg/vial long-acting injectable products should conduct claim-by-claim freedom-to-operate analysis across all six asserted patents. The portfolio spans multiple application families and formulation dimensions. Because no patent was invalidated in this case, each patent represents a live enforcement risk for future ANDA filers.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.